Free Trial
Invest Smarter with A.I. Powered Investing Tools and ResearchGet 30 Days Free

Genmab A/S (OTCMKTS:GNMSF) Reaches New 12-Month High - Time to Buy?

Written by MarketBeat
October 1, 2025
Genmab A/S logo with Medical background

Key Points

  • Genmab A/S shares reached a new 52-week high of $308.00, with a market capitalization of $20.35 billion.
  • The company reported an earnings per share (EPS) of $5.42 for the last quarter, significantly outperforming analysts' expectations of $3.99.
  • Genmab A/S develops antibody therapeutics for cancer treatment, including the drug DARZALEX for multiple myeloma patients.
  • Five stocks to consider instead of Genmab A/S.

Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) hit a new 52-week high on Wednesday . The company traded as high as $308.00 and last traded at $308.00, with a volume of 18070 shares changing hands. The stock had previously closed at $290.00.

Genmab A/S Price Performance

The stock has a market capitalization of $20.35 billion, a price-to-earnings ratio of 15.46 and a beta of 0.90. The business's 50-day simple moving average is $250.76 and its two-hundred day simple moving average is $219.71.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $5.42 EPS for the quarter, topping analysts' consensus estimates of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million for the quarter, compared to analysts' expectations of $949.06 million.

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover
Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.